Traditional Chinese medicine injections: where we are after 80-year development

Wenwen Zheng1†, Yiyang Wu2†, Hanlu Gao2 and Defang Ouyang2*

Abstract

Traditional Chinese medicine (TCM) injection is the combination of modern pharmaceutical technology and traditional Chinese prescription, which was born in 1941 and played a great role in the backward medical conditions at that time. However, the debate over TCM injections has never stopped due to adverse drug reactions (ADRs). The regulation on TCM injections has been further strengthened since 2017, which has prompted many TCM injections to carry out re-evaluations on quality, safety, efficiency as well as pharmacoeconomics, which made significant changes and progress. This review presented an up-to-date analysis of the types, amounts, and ADRs of TCM injections based on the published data and literature. This review also summarized the potential reasons for the ADRs and re-evaluation strategies. This review will provide some useful clues for TCM injections and their clinical use.

Keywords: Traditional Chinese medicine injections, Safety concern, Effectiveness, Pharmacoeconomics, Re-evaluation, Quality control

Background

Traditional Chinese medicine (TCM) injection is defined as a sterile preparation (solution, powder, concentrated solution, emulsions, etc.) intended for injecting into the human body, which is extracted from traditional Chinese herbs [1]. TCM injection is the combination of TCM theories and modern pharmaceutical technology. Compared with the traditional dosage forms (e.g. pill, powder, paste, etc.) of TCM, TCM injection has the characteristic of rapid effect, which can be used in acute and severe diseases in TCM treatments. In clinical application, TCM injections are mainly used for fighting cancer, promoting blood circulation, heat-clearing and detoxifying [2].

Unlike other TCM dosage forms that have evolved over thousands of years, TCM injection has been developed for about 80 years (Table 1). Traces of TCM injections in China can date back to the Second World War. During that period, China faced a situation where medical care was extremely lacked, and the clinical curative effect brought by traditional TCM dosage forms was also very limited. TCM injections were researched during that urgent situation. In 1941, the successful development of the Chaihu injection marked the birth of TCM injection, which saved lots of lives. In December 1954, Chaihu injection was industrialized in Wuhan Pharmaceutical Factory and became the first industrialized product of TCM injections in China. During the 1960s–1970s, TCM injections entered an era of rapid development. According to statistics, the number of TCM injection products reached 1400 in the 1980s [3]. After the 1980s, regulators began to draw up a series of regulations and drug standards to strengthen TCM injection management. However, due to the very limited research about TCM injections in the early stages, more and more safety issues of TCM injections have been exposed. Many serious adverse drug reactions (ADRs) caused by TCM injections, such as Yuxingcao injection and Ciwujia injection, have raised a lot of safety concerns about TCM injections [4]. After that, the state drug regulator issued a series of...
policies and regulations successively to promote the quality of TCM injections, emphasizing the rigorous approval and re-evaluation of injections [5–7]. In 2022, the Lianbizhi injection became the first delisted TCM injection for the reason of post-marketing evaluation failure [8].

For a long time, the adverse drug reaction (ADR) reports caused by TCM injections have resulted in hot debates on TCM injections, and also raised safety concerns among people. In recent years, especially after 2017, the strengthening supervision of TCM injections has brought changes to TCM injections. This review aims to give a summary of the changes in TCM injections from the current situation, ADRs, and re-evaluation, hoping to provide the basis for re-evaluating TCM injections and their clinical use.

Current situation of TCM injection

TCM injections are special preparations with the approval number “Z”, which means that their raw materials are Chinese herbs. On the other hand, those with the approval number “H” belong to the category of chemical drugs. Up to July 6, 2022, the data from the National Medical Products Administration (NMPA) showed that China had approved 128 TCM injections, involving 872 approval numbers and 196 manufacturing enterprises [9]. The top 15 approval numbers of TCM injections are shown in Fig. 1. Among approved TCM injections, 8 kinds of TCM injections were covered by the latest Drug Lists of National Essential Medicine (version 2018) [10]. In the latest Medicines List for National Basic Medical Insurance (version 2021), 47 TCM injection items with 44 unique serial numbers are contained and almost all of them are restricted to be used by second-class or above hospitals [11]. TCM injections have also been used in treatments during the COVID-19 pandemic. In the 4th trial version of Diagnosis and Treatment Protocol for COVID-19, four kinds of TCM injections have been recommended to treat pneumonia in China for the first time, and up to eight

| Year | Events | Description |
|------|--------|-------------|
| 1941 | Chaihu injection was successfully developed | Chaihu injection marked the birth of TCM injections |
| 1954 | Wuhan Pharmaceutical Factory put the Chaihu injection into production | The first industrially produced TCM injection in China |
| 1960s–1980s | TCM injections increased sharply | TCM injection products reached up to 1400 in the 1980s |
| 1990 | Shuanghuanglian powder injection was developed and produced by industrialization | The first TCM powder injection |
| 2006 | Yuxingcao injection was urgently stopped in the clinic | Yuxingcao injection caused 2282 ADRs from 2006 to 2008, and 22 people died [14] |
| 2007 | Released Basic technical requirements for traditional Chinese medicine and natural medicine injections | Requirements in terms of safety, effectiveness and necessity |
| 2009 | Released Notice on Carrying out the Safety Re-evaluation of Traditional Chinese Medicine Injections | The first time to propose the re-evaluation of TCM injections |
| 2010 | Proposed seven technical principles to standardize and guide the safety re-evaluation of TCM injections | These principles involve evaluation of non-clinical research, clinical research, production process, quality control, enterprise’s ability to risk control, benefits and risks, risk management |
| 2017 | Released Opinions on Deepening the Reform of the Review and Approval System and Encouraging the Innovation of Drugs and Medical Devices | Strict the review and approval of injections; Carry out the re-evaluation of injections |
| 2020 | Some TCM injections were recommended by Diagnosis and Treatment Protocol to treat pneumonia | TCM injections were mainly used to treat severe and critical illness |
| 2022 | Lianbizhi injection was delisted from the TCM market | The first TCM injection to be delisted due to re-evaluation failure |
kinds in the latest 9th version to treat severe or critically ill patients [12, 13].

**Adverse drug reactions caused by TCM injections**

TCM is rooted in the clinical practice experience for thousands of years. It is usually taken through oral administration, thus some unwanted harmful substances can be eliminated by the physiological barriers and the liver first-pass effect. However, the parenteral injection of herb extractions will bypass these barriers and enter the human body directly, which although takes effect rapidly but greatly increases the risk of side effects [15]. With the wide application of TCM injections in clinical practice, a lengthening list of adverse effects has been reported. The harmful impurities in TCM injections, such as the biological macromolecules, endotoxin, and pyrogen, are generally considered to cause ADRs. It has been found that the ADRs caused by TCM injections have the characteristics of multiple, universality, diversity and uncertainty [16]. The main ADR types of TCM injection appearing in clinical use are pyrogen reaction, allergic reaction, and anaphylactoid reaction. Among them, the anaphylactoid reaction has the highest incidence rate [17].

Figure 2 shows the statistic for the ADR reports on TCM injections in the past 10 years. In the past 10 years, the proportion of ADR reports caused by TCM to the total ADR reports is stable, while the proportion of ADR reports caused by TCM injections has changed greatly. From 2012 to 2017, ADR reports caused by TCM injections account for more than 50% of all ADR reports related to TCM. But after 2017, the proportion of TCM injection ADRs dropped significantly year by year and accounted for 27.5% of the TCM ADRs in 2021, which may be relative to the strict regulation and restricted clinic use after 2017 [7].

**Factors influencing adverse drug reaction**

**The ingredients of TCM injections are complex but poorly studied**

Different from chemical injections with well-defined ingredients, TCM injections are made from herbal extracts with complex compositions, which are very difficult to carry out research with total active components. Moreover, due to the low-level scientific research in the early period, most TCM injections only did ambiguous research on their active ingredients and harmful impurities. Thus, the safety and effectiveness of TCM injections can’t be guaranteed [18].

The pharmacokinetic study is an important method to reveal the effect and the in vivo process of active ingredients. The pharmacokinetic studies of TCM injections mainly involve the interaction within the components and the interaction studies in combination with chemical drugs. Considering the complex composition of most TCM injections and their unknown pharmacodynamic material basis, the pharmacokinetic research of TCM injections is much more difficult than that of chemical drugs. At present, the pharmacokinetic studies of TCM injections are not insufficient, especially in the human body, which leads to uncontrollable risks in clinical use [19].

**The quality of raw materials in traditional Chinese medicine is uneven**

The occurrence of ADR is mainly related to the lack of rigorous management of raw materials. TCMs are extracted from herbs, which are influenced by environmental factors, origin, agriculture, collecting, harvesting, and primary processing of raw materials [20]. The differences in the growing areas and harvesting dates have a direct impact on the effective components of traditional Chinese herbs. For example, *Fritillaria* growing in Zhejiang has different therapeutic outcomes from those growing in Sichuan, although they belong to the same genus [21]. Besides, the phenomenon of confusing the names of traditional Chinese herbs also contributes to the uneven quality of raw materials [22].

**Crude preparation process and quality control problems**

The quality control system plays a pivotal role in drug quality. The preparation processes of TCM injections determine the safety and effectiveness of the products. Compared with chemical injections, the preparation processes of TCM injections are more complicated, including extraction, filtration, precipitation, purification, sterilization, etc., which greatly increases the difficulties of quality control [23]. Furthermore, in the early years, the preparation processes of most TCM injections were simple and not refined, which made quality control even
harder. For example, the quality standards of the same TCM injection may have a big difference between different companies, and even the quality of injections by the same company may vary from batch to batch [24]. For example, a previous study tested the quality of Shuanghuanglian injections by 12 different companies and found that these injections had different content of chlorogenic acid [25]. At present, some TCM injections are still limited to using behindhand traditional preparation processes. These traditional methods have many drawbacks including a large loss of effective ingredients, insufficient removal of harmful substances, and mutual reactions between ingredients by improper process design.

**Improper clinical use**

Besides the manufacturing and quality problems of TCM injections, another issue is the irrational use of TCM injections in clinical practice. Firstly, improper use may attribute to non-standard drug instructions. As the important basis for rational drug use, the drug instruction approved by the drug administration department should contain detailed information such as drug ingredients, clinical usage and precautions [26]. However, very little information is provided in the TCM injection instructions, which provides very limited clinical guidance. Secondly, the doctors may lack knowledge of TCM. TCM injections are still based on TCM theory. Therefore, it is necessary to follow the dialectical treatment of traditional Chinese medicine theories in clinical usage. Inappropriate use of TCM injections may not only have poor therapeutic effects but also lead to adverse drug reactions [27, 28]. In addition, other clinical factors should also be mentioned, such as the selection of solvent, speed of administration, compatibility of medicines, route of administration, and dosage, which also may cause ADRs [29–31].

**Re-evaluation of TCM injections**

The early approval threshold for TCM injections was low, and most TCM injections had no thorough research on safety and efficacy [18]. In recent years, TCM injections have been questioned a lot because of frequent ADRs. Due to serious adverse events, the government must pay more attention to the quality problems of TCM injections. According to the *Opinions on Deepening the Reform of the Review and Approval System and Encouraging the Innovation of Drugs and Medical Devices* released in 2017, for the purpose of evaluating both chemical and TCM injections in safety, efficacy, and quality controllability, enterprises must conduct the comprehensive research at approval, and the post-marketing researches, including the active ingredients, mechanism of action, and clinical efficacy [7].

Recently the re-evaluation of TCM injections has achieved certain positive results. For example, the ADR proportion caused by TCM injections has decreased continually since the rigorous requirements for the injections in approval and re-evaluation were proposed in 2017 (Fig. 2). Moreover, up to July 11, 2022, the Announcements issued by NMPA revised the contents of instruction manuals for 31 kinds of TCM injections [32]. These fully affirm the validity and necessity of re-evaluation. The enterprises should evaluate and improve the quality of TCM injection products as soon as possible following the relative regulations and policies (Table 2).

**Demonstrate safety and effectiveness with scientific evidence**

Efficacy is the key to a drug. Usually, a drug must be evaluated in strict scientific clinical trials with hundreds to thousands of patients. However, due to the low level of research and limited technical conditions at the early stage, most TCM injections did not undergo rigorous clinical trials before approval [33]. Up to July 6, 2022, only 21 kinds of TCM injections among 128 approved TCM injections had relevant clinical trial information in the ClinicalTrials.gov database [34].

In clinical practice, TCM injections are mostly used in combination with other chemical drugs. For instance, among 4382 cases associated with the Shuanghuanglian injection in the clinic, 82.79% of injections were used in combination with antibiotic drugs [35]. It is quite necessary to use reliable and scientific evidence to evaluate the efficacy of TCM injections being used alone [36]. If the real efficacy of TCM injections is not clear, it is hard to distinguish their real contribution to combination therapies.

Identifying the material basis of TCM injections is a prerequisite for evaluating clinical efficacy and safety. In 2006, the *Basic Technical Requirements for Traditional Chinese Medicine and Natural Medicine Injection* made requirements on the ingredients of TCM injection [5]: for injections made of active ingredients, the content of a single ingredient should be no less than 90%; for multi-component TCM injections, the content of well-defined components in the total solids should be no less than 60% and the measurable components should be no less than 80% of total solids; raw materials, intermediates and preparations should be studied to establish fingerprints respectively, and the correlation study between them should be carried out; the components whose structure is clarified should be reflected in the fingerprint, generally not less than 90% of clarified components. These requirements are collectively called 689 Principle. A previous review summarized that some TCM injections have satisfied the requirements of 689 Principle, some even with
higher standards [37]. For example, a company claimed on its website that they have completed a study of the material basis of Tanreqing injection: among the total solids of Tanreqing injection, the structures of over 80% of components are well-defined, over 80% of components are measurable, and 93% of the well-defined components can be identified in the fingerprints [38].

Pharmacokinetic studies investigate drug action mechanisms and in vivo processes, which can provide scientific guidance for clinical uses. In recent years, some pre-clinical and clinical pharmacokinetic studies have been carried out for the re-evaluation of TCM injections. However, most of them focused on pre-clinical research, while only a few studies related to clinical studies [19]. It is well-known that the clinical pharmacokinetic study in the human body is of great significance for the safety and effectiveness of a drug in clinical uses. Thus, more large-scale and standardized clinical trials of TCM injections should be carried out in the future.

Evidence-based medicine is another powerful method for evaluating the efficacy of TCM injections. A number of TCM injection studies related to randomized control trials (RCTs) and meta-analysis were published every year [39–41]. Danhong injection (DHI) is a kind of multi-target drug. To evaluate the efficacy and safety of DHI to treat symptomatic chronic stable angina, a rigorously designed randomized controlled trial was conducted in 920 patients with moderate symptomatic stable angina. The results showed that after 14-day of DHI use, the angina episodes were significantly reduced and without any additional risk. The follow-up visit found that the health condition specific to angina was improved for at least 90 days. This study further identified the anti-angina therapeutic modules of DHI on the effective population, at least 90 days. This study further identified the anti-angina therapeutic modules of DHI on the effective population, at least 90 days. This study further identified the anti-angina therapeutic modules of DHI on the effective population, at least 90 days. This study further identified the anti-angina therapeutic mechanisms and in vivo processes, which can provide scientific guidance for clinical uses. In recent years, some pre-clinical and clinical pharmacokinetic studies have been carried out for the re-evaluation of TCM injections. However, most of them focused on pre-clinical research, while only a few studies related to clinical studies [19]. It is well-known that the clinical pharmacokinetic study in the human body is of great significance for the safety and effectiveness of a drug in clinical uses. Thus, more large-scale and standardized clinical trials of TCM injections should be carried out in the future.

Evidence-based medicine is another powerful method for evaluating the efficacy of TCM injections. A number of TCM injection studies related to randomized control trials (RCTs) and meta-analysis were published every year [39–41]. Danhong injection (DHI) is a kind of multi-target drug. To evaluate the efficacy and safety of DHI to treat symptomatic chronic stable angina, a rigorously designed randomized controlled trial was conducted in 920 patients with moderate symptomatic stable angina. The results showed that after 14-day of DHI use, the angina episodes were significantly reduced and without any additional risk. The follow-up visit found that the health condition specific to angina was improved for at least 90 days. This study further identified the anti-angina therapeutic mechanisms and in vivo processes, which can provide scientific guidance for clinical uses. In recent years, some pre-clinical and clinical pharmacokinetic studies have been carried out for the re-evaluation of TCM injections. However, most of them focused on pre-clinical research, while only a few studies related to clinical studies [19]. It is well-known that the clinical pharmacokinetic study in the human body is of great significance for the safety and effectiveness of a drug in clinical uses. Thus, more large-scale and standardized clinical trials of TCM injections should be carried out in the future.

**Table 2** Comparisons between the TCM injection regulation status and the requirements for general injections

| Requirements for general injections | TCM injection regulation status |
|------------------------------------|--------------------------------|
| Pre-clinical research | Definitive studies of all components in the injection, including the structures and properties of components and interactions between components | • The complexity of Chinese herbal medicines makes it difficult to identify the active ingredients and the harmful substances |
| Clinical research | Large-scale and high-quality clinical trials are required to demonstrate the safety and efficacy of the injections | • Did not undergo rigorous clinical trials when TCM injections were approved |
| Preparation process and quality control | • For chemical injection, the production processes are relatively simple and controllable • Modern manufacture with advanced technologies | • The production processes are more complicated, making quality control very difficult |
| | • Specific quality control will be used for each well-defined ingredient in the injections • The indicators usually specify the upper and lower limits of the component contents | • Outdated preparation methods such as the alcohol-water method are still adopted by some TCM injections on the market |
| Post-market regulation | • Submit information on side effects and quality management to the authorities regularly • Some injections will require Phase IV clinical trials | • Limited control is used for complicated TCM injections, only a few components are tested for quality control |

**Strengthen the quality management of raw herb materials**

As one of the dosage forms with the highest quality requirements, TCM injection is required higher standards of consistency and controllability than other traditional Chinese medicine products. As the important raw materials for TCM injection production, the quality of medicinal plant raw materials should be controlled first.

In 2002, the first *Quality Management Standards of Chinese Herbal Medicine* was released to control the quality of herb medicine by using Good Agricultural Practice (GAP) [43]. GAP is the basic criterion to standardize the production and management of Chinese herbs, and regulates the processes of herbs such as collection, storage, and processing. As of February 2016, 167 kinds of Chinese herbal medicines from 129 companies have passed the GAP certification [44]. But this GAP was canceled in 2016 because it played a...
limited role in the continual management. In 2022, the new GAP certification was released to further promote the standardized production of Chinese herbal medicine [45]. Compared with the old version of GAP, the newly released GAP further refines the whole process of quality management in Chinese herbs. Enterprises should strengthen their management of the quality of raw materials from the herb source by new GAP standards.

Modernize the preparation processes and improve the quality control
Most enterprises still adopt outdated methods and low-standard quality control. To ensure high-standard and controllable production processes, enterprises should speed up their transformation to more advanced and scientific production processes. In 2016, the NMPA clarified the requirements for enterprises to achieve drug traceability [46]. The quality traceability system refers to recording the drug information from manufacture to market to quickly and effectively trace any quality issues. A good traceability system is very important to the quality management of TCM injections. For example, although the Xiyanping injection has completed a large number of non-clinical safety and pharmacology studies and post-marketing clinical safety studies from 2009 to 2013 [47], this TCM injection was still urgently recalled for causing severe adverse reactions such as chills and fever in 2017 [48]. This gives us enlightenment that a one-time evaluation cannot ensure the life-long safety of a drug, and safety evaluation should be a systematic project that runs through the entire life cycle of TCM injections.

Pharmacoeconomics evaluation of TCM injections
The purpose of the pharmacoeconomic evaluation is to rationally select and use drugs to achieve efficient, safe, and economical use of limited medical and health resources to get the optimal treatment effect and the minimal economic burden. TCM injections occupy a huge share of the TCM market compared with other dosage forms of TCMs, accounting for one-third of the total TCM sales in hospitals [49], while the therapeutic effects of TCM injections in clinical use do not match the high investment. For example, one study showed that the cost of Shuanghuanglian injection and Qingkailing injection was nearly 10 to 30 times higher than that of oral dosage forms when obtaining the same therapeutic effect [50]. In order to effectively control unnecessary drug costs, on the one hand, the clinical cost and effectiveness of commonly used TCM injections in National Basic Medical Insurance should be investigated to compare with other alternative dosage forms. On the other hand, the cost of ADR treatment from TCM injections should be monitored too.

Conclusion
Current paper summarized and discussed the brief history, current situation, ADRs, and re-evaluation and progress of TCM injections. Due to the limited research on TCM injections at the early stage, there was insufficient evidence in nearly all aspects of clinical efficiency, safety, quality control, manufacturing process, and pharmacoeconomics to support the clinical usage of most TCM injections. TCM injections are currently at a critical moment to do the post-marketing evaluation. Although the qualities of some TCM injections have been improved in recent years, re-evaluation of TCM injections needs to be further promoted to obtain more acceptance and recognition. For instance, the quality management of raw herbs should be strengthened; convincible studies of material basis and pharmacokinetics should be finished; the modernization of preparation processes should be accelerated; the necessity for using TCM injections should be assessed through pharmacoeconomic evaluation. In general, the post-market evaluation has played a positive role in the quality control of TCM injections. Under the increasingly strict requirement of the government and market, the quality control and clinic use of TCM injections will be more standardized.

Abbreviations
TCM: Traditional Chinese medicine; TCMs: Traditional Chinese medicines; ADR: Adverse drug reaction; ADRs: Adverse drug reactions; NMPA: The National Medical Products Administration; RCTs: Randomized control trials; GAP: Good Agriculture Practice; DHI: Danhong injection; EVDS: The Traditional Chinese Medicine Clinical Evidence Database System.

Acknowledgements
Not applicable.

Author contributions
WZ, YW and HG: writing, reviewing and editing the manuscript. DO: conceptualization, supervision, review and editing the manuscript. All authors read and approved the final manuscript.

Funding
Current research is financially supported by the Science and Technology Development Fund (FDCT/0108/2021/A).

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
All authors consent to the publication of this work in Chinese Medicine.
Competing interests
The authors declare no competing interests.

Author details
1 Department of Clinical Laboratory, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. 2 State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences (ICMS), University of Macau, Macau, China.

Received: 7 August 2022   Accepted: 26 October 2022
Published online: 08 November 2022

References
1. Tan L, Wang M, Zhu Y. Research progress of adverse reactions of traditional Chinese medicine injections. China J Chin Mater Med. 2014;39:3889–98. [in Chinese].

2. Xu L, Liu J, Zou L. Current situation analysis and prospects of traditional Chinese medicine injection. J Chengdu Univ Technol (Sci Technol Ed). 2013;32:215–8. [in Chinese].

3. Bai X. An analysis of the current situation and countermeasures for the drug lists of national essential medicine (version 2018). 2018. http://www.nmpa.gov.cn/fgw/gzlj/gzjy/20071206120001186. html. Accessed 30 July 2022 (in Chinese).

4. Ji K, Chen J, Li M, Liu Z, Xia L, Wang C, et al. Comments on serious anaphylaxis caused by nine Chinese herbal injections used to treat common colds and upper respiratory tract infections. Regul Toxicol Pharmacol. 2009;55:134–8.

5. Notice on printing and distributing basic technical requirements for traditional Chinese medicine and natural medicine injections. 2007. https://www.nmpa.gov.cn/fgw/gzlj/gzjy/20090113120001613.html. Accessed 30 July 2022 (in Chinese).

6. Notice on carrying out the safety re-evaluation of traditional Chinese medicine injections. 2009. https://www.nmpa.gov.cn/xgk/fgw/gzlj/gzjy/20200901120001106.html. Accessed 30 July 2022 (in Chinese).

7. The General Office of the Central Committee of the Communist Party of China and the General Office of the State Council issued the opinions on deepening the reform of the review and approval system and encouraging the innovation of medicines and medical devices. 2017. http://www.gov.cn/zhengce/2017-10/08/content_52301055.htm. Accessed 30 July 2022 (in Chinese).

8. Announcement of the National Medical Products Administration on the cancellation of the drug registration certificate of Lianbizhi injection (No. 2 of 2022). 2022. https://www.nmpa.gov.cn/ypgzt/yqjggs/20220111102101146.html?ypcm=7. Accessed 07 Oct 2022 (in Chinese).

9. The General Office of the State Council issued the opinions on the further deepening of the review and approval system and encouraging the innovation of medicines and medical devices. 2017. http://www.nmpa.gov.cn/rmmbt/2017/1213379275816856401899. Accessed 30 July 2022 (in Chinese).

10. Drug lists of national essential medicine (version 2018). 2018. http://www.nhc.gov.cn/wjw/jyjyzs/201710/6008956494740eb9eebe729cf426fbd57.shtml. Accessed 30 July 2022 (in Chinese).

11. Medicines list for national basic medical insurance (version 2021). 2021. http://www.gov.cn/zhengce/zhengceku/2021-12/03/content_5655651.htm. Accessed 30 July 2022 (in Chinese).

12. The general office, National Health Commission, the Office of the National Administration of Traditional Chinese Medicine. Notice on issuing the diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 4). 2020. http://www.nhc.gov.cn/zyyj/s7653p/202001/4294569353b432009b31739bd0785e67.html. Accessed 30 July 2022 (in Chinese).

13. The general office, National Health Commission, the Office of the National Administration of Traditional Chinese Medicine. Notice on issuing the diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 9). 2022. http://www.nhc.gov.cn/zyyj/s7653p/202203/b74ade1ba4949e838850a37a40093d88.html. Accessed 30 July 2022 (in Chinese).

14. Wu J, Yang X, Liu Q, Yin P, Zeng F. Post-market re-evaluation on safety of Yuxingcao (Houttuyniae Herba) preparations. Her Med. 2016;35:803–8. [in Chinese].

15. Jia H, Zhao J, Liang T, Guan Q. Dialectical use of traditional Chinese medicine injections to ensure the safety and effectiveness in clinical practice. Glob Tradit Chin Med. 2016;9:49–53. [in Chinese].

16. Pan J. Characteristics of adverse reactions of traditional Chinese medicine injection and analysis of clinical rational drug use. J North Pharm. 2015;12:104–5. [in Chinese].

17. Yan YL, Chunying L, Aihua L, Jingzhou T, Yong Z. Pseudoallergic reactions during post-marketing non-clinical safety reevaluation of traditional Chinese medicine injections. Chin J Pharmacovigil. 2022;19:185–8. [in Chinese].

18. Wu H, Chen Y, Zhu Y, Li Y, Qu P, Li Z, et al. Research progress of re-evaluation of traditional Chinese medicine injection. Chin J Ethnomed Ethnopharm. 2022;31:41–5. [in Chinese].

19. Liu Y, Zhan S, Zheng B, Fang M, Feng Y, Zhang J, et al. Advance on pharmacokinetics study of traditional Chinese medicine injections in recent ten years. China J Chin Mater Med. 2021;46:1752–62. [in Chinese].

20. Bian Z, Shang H, Wu T, Li Y, Zhang BL. Review of adverse reactions to Chinese medicine injections. Chin J Evol-Based Med. 2010;10:116–21. [in Chinese].

21. Duan B, Huang L, Chen S. Study on the destructive effect to inherent quality of Fritillaria thunbergii Meq. (Zhebeimu) by sulfur-fumigated process using chromatographic fingerprinting analysis. Phytotherapy. 2012;19:562–8 [in Chinese].

22. Zhu Z, Luo C, Ren D, Feng L. Traditional Chinese medicine name, scientific name and Chinese name of original plants. Chin J Exp Tradit Med Formulae. 2017;23:65–70. [in Chinese].

23. Wang J. Current situation and development trends of production processes of traditional Chinese medicine injection. Pop Sci Technol. 2021;23:65–7 [in Chinese].

24. Zhou Q, Sun S, Zuo L. Study on traditional Chinese medicine ‘Qing Kai Ling’injections from different manufactures by 2D IR correlation spectrosopy. Vib Spectrosc. 2004;36:207–12.

25. Cheng F, Liu Z. Safety evaluation of traditional Chinese medicine injections and study of related key technology. China J Chin Mater Med. 2009;34:1052–4. [in Chinese].

26. Liu L, Fan Z. Viewing the clinical application of drug instructions with legal thinking. Chin J Clin Pharmacol. 2020;36:456–7 [in Chinese].

27. Li J, Tian L. Analysis of rationality of solvents and indications for using TCM injections in our hospital. China Pharm. 2015;26:3204–5. [in Chinese].

28. Zheng S, Huang B, Li J. Pareto diagram analysis on 1000 irrational medication orders of traditional Chinese medicine injections. Eval Anal Drug Use Hosp China. 2020;596–8+642 [in Chinese].

29. Du X, Sun J, Duan J, Fan X, Guo J. Literature study of drug combination type and incompatibility of traditional Chinese medicine injections. Chin J Pharmacovigil. 2014;11:432–46 [in Chinese].

30. Wang M. Analysis on the use condition of TCM injections solvent. J Hubei Univ Chin Med. 2016;18:43–5 [in Chinese].

31. Shi H, Xu B, Ge Q. Discussion on safe use of TCM injection from the choice of menstruum. China Pharm. 2012;23:4125–6 [in Chinese].

32. Drug instructions amendment notice. 2009. http://www.nmpa.gov.cn/directoryweb/nmpa/fgw/ggtg/yyszhsxdggs/index.html. Accessed 30 July 2022 (in Chinese).

33. Mei Q. Causes for adverse reactions of traditional Chinese medicine injections: a case study of the “Houttuynia Cordata injection event.” China Pharm. 2007;18:401–3 [in Chinese].

34. Mei Q. Causes for adverse reactions of traditional Chinese medicine injections: a case study of the “Houttuynia Cordata injection event.” China Pharm. 2007;18:401–3 [in Chinese].

35. Zhou C, Xu Z, Lin Y. Attention should be paid to the post-marketing reevaluation of traditional Chinese medicine injection. Chin J Pharma- covigil. 2006;129–30 [in Chinese].

36. Zhong Y, Mao B, Wang G, Fan T, Liu X, Diao X, et al. Tanreqing injection combined with conventional western medicine for acute exacerbations of chronic obstructive pulmonary disease: a systematic review. J Altern Complement Med. 2010;16:1309–19.

37. He Z, Wang Q, Liu M, Wu T, Ouyang D. Research progress on quality control of traditional Chinese medicine injection. Chin J Pharm. 2021;52:599–610 [in Chinese].

38. Based on Tanreqing, Kai Bao Pharmaceutical is the guardian of people's life and health! 2002. http://www.xykb.com/newsinfo/556279.html. Accessed 07 Oct 2022 (in Chinese).
39. Ma Q, Qiu M, Zhou H, Chen J, Yang X, Deng Z, et al. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical corona virus disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2. Pharmacol Res. 2020;160: 105073.

40. Liu J, Li D, Dong W, Liu Y-Q, Wu Y, Tang D, et al. Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection: a randomized trial. Sig Transduct Target Ther. 2021;6:1–10.

41. Zhou Y, Zhao B, Wu W, Yang X, Long S, Deng H, et al. Shenmai injection for the treatment of cancer-related fatigue in advanced non-small cell lung cancer patients undergoing chemotherapy: study protocol for a randomized controlled trial. Trials BioMed Central. 2018;19:1–9.

42. TCM clinical evidence database. https://tcmevd.com/evidence/index. Accessed 30 July 2022 (in Chinese).

43. Chinese herbal medicine production quality management standard (trial). 2002. https://www.nmpa.gov.cn/directory/web/nmpa/xzgl/fgw/bmgzh/20020417010101413.html. Accessed 30 July 2022 (in Chinese).

44. Yang G, Guo P, Zhou X, Qi H. Analysis of several key problems of good agricultural practice (GAP) of Chinese materia medica. China J Chin Mater Med. 2016;41:1173–7 (in Chinese).

45. Chinese herbal medicine production quality management standard. 2022. https://www.nmpa.gov.cn/directory/web/nmpa/xzgl/qgtg/yqmgz/20220317110344133.html. Accessed 30 July 2022 (in Chinese).

46. Announcement of the general administration on amending the appendices related to the good manufacturing practice for pharmaceuticals. 2016. https://www.nmpa.gov.cn/directory/web/nmpa/yaoqin/yqmgz/ypmgz/20161229172101647.html. Accessed 30 July 2022 (in Chinese).

47. Wang Z, Chen X, Zhang W, Xie Y. Literature review on premarketing and postmarketing evidence of Xiyanping injection. China J Chin Mater Med. 2014;39:3637–40 (in Chinese).

48. Notice of the general administration on the quality problems of Honghua Injection from Shanxi Zhendong Ante Biopharmaceutical Co., Ltd. and Xiyanping injection from Jiangxi Qingfeng Pharmaceutical Co., Ltd. 2017. https://www.nmpa.gov.cn/xgk/qgtg/20170923225201502.html?type=pc&m=. Accessed 30 July 2022 (in Chinese).

49. Li H, Wang S, Yue Z, Ren X, Xia J. Traditional Chinese herbal injection: current status and future perspectives. Fitoerapia. 2018;129:249–56.

50. Zhang F, Zhou C. Illumination of pharmacoeconomics on Chinese herbal medicine inject. China J Chin Mater Med. 2007;32:453–6 (in Chinese).

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.